Clinical trial
Paricalcitol in Treating Patients With Myelodysplastic Syndrome
NCT00064376 · Cedars-Sinai Medical Center, Other · Completed
Key facts
| NCT number | NCT00064376 |
|---|---|
| Title | Paricalcitol in Treating Patients With Myelodysplastic Syndrome |
| Official title | A Phase II Trial Of Paricalcitol In Myelodysplastic Syndromes |
| Lead sponsor | Cedars-Sinai Medical Center, Other |
| Collaborators | Abbott Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | paricalcitol |
| Start date | May 1, 2003 |
| Primary completion | Nov 1, 2005 |
| Completion | Nov 1, 2005 |
| First posted | Jul 9, 2003 |
| Last update posted | Jan 29, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: